DEFA14A 1 ndra_def14a.htm PRIMARY DOCUMENT ndra_def14a

Washington, D.C. 20549
(Rule 14a-101)
Proxy Statement Pursuant to Section 14(a) of the Securities
Exchange Act of 1934 (Amendment No. )
Filed by the Registrant
Filed by a Party other than the Registrant
Check the appropriate box:
Preliminary Proxy Statement
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
Definitive Proxy Statement
Definitive Additional Materials
Soliciting Material Pursuant to Rule 14a-12
(Name of Registrant as Specified in its Charter)
(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)
Payment of Filing Fee (Check the appropriate box):
No fee required.
Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
Title of each class of securities to which transaction applies: N/A
Aggregate number of securities to which transaction applies: N/A
Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): N/A
Proposed maximum aggregate value of transaction:
Total fee paid: N/A
Fee paid previously with preliminary materials.
Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
Amount Previously Paid: N/A
Form, Schedule or Registration Statement No.: N/A
Filing Party: N/A
Date Filed: N/A

3600 Green Court, Suite 350
Ann Arbor, Michigan 48105
August 10, 2020
To the Stockholders of ENDRA Life Sciences Inc. (the “Company”):
The Company has extended the expiration date for its current Consent Solicitation, currently set to expire on August 13, 2020, to 5:00 p.m. Eastern Time on August 20, 2020, subject to early termination or extension in the Company’s discretion, to allow more opportunity for stockholders to submit consents on the proposal described in the Company’s definitive Consent Solicitation Statement filed with the Securities and Exchange Commission (the “SEC”) on August 3, 2020, which is a proposal to approve the potential issuance of shares of the Company’s common stock upon the exercise of certain warrants at reduced exercise prices, in compliance with Nasdaq Stock Market Rule 5635(d).
Only stockholders of record of the Company’s common stock and preferred stock as of the close of business on July 7, 2020 are entitled to submit Action by Written Consent forms in connection with the Consent Solicitation. All stockholders who have previously voted in the Consent Solicitation do not need to re-vote or take any other action; executed written consents delivered to the Company are not revocable.
No changes have been made in the proposal for which consent is solicited as described in the Consent Solicitation. THE COMPANY STRONGLY ADVISES ALL OF ITS STOCKHOLDERS TO READ THE CONSENT SOLICITATION STATEMENT BECAUSE IT CONTAINS IMPORTANT INFORMATION. SUCH CONSENT SOLICITATION STATEMENT IS AVAILABLE AT NO CHARGE ON THE SEC’S WEBSITE AT WWW.SEC.GOV. In addition, copies of the Consent Solicitation Statement may be obtained free of charge by accessing the Company’s website at or by contacting the Company at (734) 335-0468 or by mail to 3600 Green Court, Suite 350, Ann Arbor, MI 48105.
/s/ David Wells
David Wells
Chief Financial Officer and Secretary